5-溴-2-甲基苯磺酰氯 | 69321-56-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-2-甲基苯磺酰氯
• 英文名称: 5-bromo-2-methyl-benzene-sulfonyl chloride
• 英文别名: 5-bromo-2-methylbenzenesulphonyl chloride；5-Bromo-2-methylbenzene-1-sulfonyl chloride；5-bromo-2-methylbenzenesulfonyl chloride
• CAS: 69321-56-8
• 化学式: C₇H₆BrClO₂S
• mdl: MFCD06655596
• 分子量: 269.546
• InChiKey: OYSAFEFFWRNQJF-UHFFFAOYSA-N

物化性质

• 沸点：
  333.1±35.0 °C(Predicted)
• 密度：
  1.700±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2904909090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  3261
• 危险性描述：
  H314

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-2-methylbenzenesulfonyl chloride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-2-methylbenzenesulfonyl chloride
CAS number: 69321-56-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6BrClO2S
Molecular weight: 269.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-2-甲基苯磺酰氯 在 氯仿 、 氨 作用下， 生成 4-溴苯甲烷磺酰胺
  参考文献：
  名称：

  Clutterbuck; Cohen, Journal of the Chemical Society, 1923, vol. 123, p. 2510

  摘要：

  DOI：
• 作为产物：
  描述：

  对溴甲苯 在 氯磺酸 作用下， 以 氯仿 为溶剂， 反应 4.0h， 以78%的产率得到5-溴-2-甲基苯磺酰氯
  参考文献：
  名称：

  N-乙酰基-2-羧基苯磺酰胺的设计，合成和生物学评估：一类新型的环氧合酶2（COX-2）抑制剂。

  摘要：

  N-乙酰基-2-羧基苯磺酰胺（11）和一组具有适当取代的苯基取代基的类似物（4-F，2,4-F（2），4-SO（2）Me，4-OCHMe（2 ））合成附着在其C-4或C-5位置的化合物，作为选择性的环氧合酶2（COX-2）抑制剂进行评估。体外COX-1 / COX-2抑制研究表明，与阿司匹林（COX-1 IC（ 50）= 0.35microM； COX-2 IC（50）= 2.4microM），与阿司匹林一样[COX-2选择性指数（SI）= 0.14]，11是非选择性COX-2抑制剂（COX-2 SI = 0.23） 。具有连接到C-4的2,4-二氟苯基取代基的区域异构体（COX-2 IC（50）= 0.087microM; COX-2 SI> 1149）或C-5（COX-2 IC（50）= 0.77microM ，SI> 130），相对于参考药物塞来昔布（11）的位置表现出最有效和选择性的COX-2抑制活性（COX-1

  DOI：

  10.1016/j.bmc.2005.01.039
• 作为试剂：
  描述：

  氯磺酸 、 对溴甲苯 、 在 乙酸乙酯 、 Sodium sulfate-III 、 5-溴-2-甲基苯磺酰氯 作用下， 反应 3.0h， 以This resulted in 5-bromo-2-methylbenzene-1-sulfonyl chloride (30 g) as light yellow oil的产率得到5-溴-2-甲基苯磺酰氯
  参考文献：
  名称：

  SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS

  摘要：

  本发明涉及一系列具有一般式（I）的取代化合物，包括其立体异构体和/或其药学上可接受的盐，其中R1、R2、R3、R4、R5和R6如本文所定义。本发明还涉及制备这些化合物的方法，包括中间体。本发明的化合物在kappa (κ) 阿片受体 (KOR) 位点上具有有效性。因此，本发明的化合物在制药剂中是有用的，特别是在治疗和/或预防各种中枢神经系统疾病 (CNS) 中，包括但不限于急性和慢性疼痛及相关疾病，尤其在中枢神经系统周边的功能方面。

  公开号：

  US20150031685A1

文献信息

• Synthesis of symmetrical and unsymmetrical 1,3-diheteroarylbenzenes through palladium-catalyzed direct arylation of benzene-1,3-disulfonyl dichloride and 3-bromobenzenesulfonyl chlorides
  作者：Imane Idris、Fazia Derridj、Safia Djebbar、Jean-François Soulé、Henri Doucet

  DOI：10.1016/j.tet.2015.10.082

  日期：2015.12

  The palladium-catalyzed synthesis of unsymmetrical 1,3-diheteroarylbenzenes was investigated. The first synthetic pathway relies on the desymmetrization of benzene-1,3-disulfonyl dichloride through two successive palladium-catalyzed direct desulfitative arylations with two different heteroarenes. The second strategy employs the orthogonal functionalization of 3-bromobenzenesulfonylchloride using an

  研究了钯催化的不对称1,3-二杂芳基苯的合成。第一个合成途径依赖于苯-1,3-二磺酰二氯通过两个连续的钯催化的具有两个不同杂芳基的直接脱硫芳基化反应的脱对称化。第二种策略是使用C–H键重复芳基化序列对3-溴苯磺酰氯进行正交官能化，即钯催化的直接脱硫芳基化，然后以芳基溴化物为偶合伙伴进行钯催化的直接芳基化步骤。还研究了对称的1,3-二杂芳基苯的合成。
• Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition
  作者：Phillip P. Sharp、Jean-Marc Garnier、David C. S. Huang、Christopher J. Burns

  DOI：10.1039/c4md00182f

  日期：——

  This work provides new insights into a range of acetyl-lysine mimetics as BET bromodomain inhibitors.

  这项工作为BET溴结构域抑制剂中的一系列乙酰赖氨酸类似物提供了新的见解。
• [EN] PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY<br/>[FR] PYRAZOLO[1,5-A]PYRIDINES ET LEUR UTILISATION EN CANCÉROTHÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2009008748A1

  公开（公告）日：2009-01-15

  Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  Pyrazolo[1,5-a]吡啶类化合物被描述，包括它们的制备方法，以及它们作为抗癌治疗药物或药剂的用途，无论是单独使用还是与放疗和/或其他抗癌药物联合使用。
• Acetylenyl-pyrazolo-pyrimidine derivatives
  申请人：McArthur Gatti Silvia

  公开号：US20060217387A1

  公开（公告）日：2006-09-28

  The present invention relates to compounds of formula (I): wherein R 1 to R 3 , A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.

  本发明涉及式(I)的化合物：其中R1到R3、A、M、L、E、G和J的定义如描述和索赔中所述。该发明还涉及一种制备此类化合物的方法、含有它们的药物组合物，以及治疗中枢神经系统疾病的方法。
• [EN] SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS<br/>[FR] ACÉTAMIDES HÉTÉROCYCLIQUES SUBSTITUÉS EN TANT QU'AGONISTES DU RÉCEPTEUR OPIOÏDE KAPPA (KOR)
  申请人：REDDYS LAB LTD DR

  公开号：WO2013131408A1

  公开（公告）日：2013-09-12

  The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

  本发明涉及一系列具有通式（I）的取代化合物，包括它们的立体异构体和/或其药用盐，其中R1、R2、R3、R4、R5和R6如本文所定义。本发明还涉及制备这些化合物的方法，包括中间体。本发明的化合物在kappa（κ）阿片受体（KOR）位点上具有有效性。因此，本发明的化合物可用作药物剂，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面，包括但不限于急性和慢性疼痛，以及相关疾病，尤其是在中枢神经系统的外周起作用。